Table 1 Demographic, clinical and mutational data of the patients included in the study
Total cases | 1282 |
|---|---|
Age, median (IQR) | 67 (60–73) |
≤ 50, n (%) | 100 (8.5) |
> 50, n (%) | 1182 (91.5) |
Males, n (%) | 848 (66) |
Never smokers/ data available, n (%) | 140/780 (17.9) |
EGFR mutated/ analyzed (%) | 176/1282 (13.7) |
Exon 18, n (%) | 11 (6.2) |
Exon 19, n (%) | 89 (50) |
Exon 21, n (%) | 78 (43.8) |
KRAS mutated/analyzed (%) | 201/944 (21.3) |
Exon 2, n (%) | 171 (85.1) |
G12C | 68 (39.8) |
G12V | 38 (22.2) |
G12D | 34 (19.9) |
Other G12 | 21 (12.3) |
G13D | 10 (5.8) |
Exon 3, n (%) | 30 (14.9) |
Q61H | 15 (50) |
Q61L | 15 (50) |
BRAF V600E mutated/analyzed (%) | 28/944 (3) |
ALK rearranged/analyzed (%) | 41/880 (4.7) |
MET amplified/analyzed (%) | 14/692 (2) |
Concomitant genetic alterations | |
EGFR + MET, n (%) | 2 (0.3) |
ALK + MET, n (%) | 2 (0.3) |
Follow-up time, mean (± SD), months | 46.1 (± 27.4) |
Survival, mean (± SD), months | 19.9 (± 22.4) |